Parnax Lab Ltd
Incorporated in 1985, Parnax Lab Ltd manufactures and exports Pharmaceutical Formulations[1]
- Market Cap ₹ 146 Cr.
- Current Price ₹ 127
- High / Low ₹ 168 / 55.0
- Stock P/E 61.0
- Book Value ₹ 17.4
- Dividend Yield 0.00 %
- ROCE 9.42 %
- ROE 8.12 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
- Debtor days have improved from 71.3 to 52.8 days.
Cons
- Stock is trading at 7.47 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- The company has delivered a poor sales growth of 5.19% over past five years.
- Company has a low return on equity of 2.27% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
57.40 | 27.73 | 19.45 | 15.86 | 7.12 | 5.28 | 5.80 | 6.49 | 7.68 | 2.37 | 7.15 | 7.47 | 8.17 | |
63.14 | 26.85 | 19.57 | 16.19 | 7.52 | 4.66 | 6.68 | 6.38 | 7.15 | 2.82 | 5.78 | 5.86 | 5.29 | |
Operating Profit | -5.74 | 0.88 | -0.12 | -0.33 | -0.40 | 0.62 | -0.88 | 0.11 | 0.53 | -0.45 | 1.37 | 1.61 | 2.88 |
OPM % | -10.00% | 3.17% | -0.62% | -2.08% | -5.62% | 11.74% | -15.17% | 1.69% | 6.90% | -18.99% | 19.16% | 21.55% | 35.25% |
0.57 | 0.94 | 0.85 | 0.78 | 0.66 | 0.28 | 0.13 | 0.51 | 0.42 | 0.07 | 0.16 | 0.33 | 0.55 | |
Interest | 1.72 | 1.55 | 1.39 | 1.41 | 1.09 | 1.33 | 1.28 | 1.08 | 1.38 | 0.83 | 0.71 | 0.25 | 0.15 |
Depreciation | 0.78 | 0.75 | 0.80 | 0.80 | 0.60 | 0.53 | 0.44 | 0.05 | 0.04 | 0.04 | 0.04 | 0.07 | 0.07 |
Profit before tax | -7.67 | -0.48 | -1.46 | -1.76 | -1.43 | -0.96 | -2.47 | -0.51 | -0.47 | -1.25 | 0.78 | 1.62 | 3.21 |
Tax % | 31.55% | 16.67% | 17.81% | 31.82% | 28.67% | 30.21% | 3.24% | -62.75% | -325.53% | 9.60% | 30.77% | 25.93% | |
-5.25 | -0.39 | -1.21 | -1.20 | -1.01 | -0.67 | -2.40 | -0.83 | -2.00 | -1.13 | 0.54 | 1.20 | 2.39 | |
EPS in Rs | -6.17 | -0.46 | -1.42 | -1.41 | -1.19 | -0.79 | -2.82 | -0.98 | -2.35 | -1.33 | 0.55 | 1.04 | 2.08 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | -12% |
5 Years: | 5% |
3 Years: | -1% |
TTM: | 7% |
Compounded Profit Growth | |
---|---|
10 Years: | 18% |
5 Years: | 21% |
3 Years: | 38% |
TTM: | 163% |
Stock Price CAGR | |
---|---|
10 Years: | 11% |
5 Years: | 33% |
3 Years: | 76% |
1 Year: | 71% |
Return on Equity | |
---|---|
10 Years: | -8% |
5 Years: | -5% |
3 Years: | 2% |
Last Year: | 8% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 8.50 | 8.50 | 8.50 | 8.50 | 8.50 | 8.50 | 8.50 | 8.50 | 8.50 | 8.50 | 9.81 | 11.49 | 11.49 |
Reserves | 6.92 | 6.53 | 5.31 | 4.12 | 3.10 | 2.48 | 0.15 | -0.68 | -2.68 | -3.79 | 1.12 | 7.87 | 8.53 |
16.57 | 16.13 | 16.56 | 18.90 | 16.91 | 12.12 | 12.40 | 11.23 | 11.06 | 11.41 | 9.20 | 1.07 | 0.63 | |
6.73 | 7.57 | 6.43 | 3.65 | 1.75 | 1.73 | 2.11 | 1.36 | 1.77 | 1.52 | 3.40 | 0.94 | 0.94 | |
Total Liabilities | 38.72 | 38.73 | 36.80 | 35.17 | 30.26 | 24.83 | 23.16 | 20.41 | 18.65 | 17.64 | 23.53 | 21.37 | 21.59 |
9.30 | 8.65 | 8.00 | 7.28 | 6.69 | 6.36 | 0.62 | 0.57 | 0.53 | 0.49 | 0.44 | 0.43 | 0.52 | |
CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 10.69 | 10.71 | 10.71 | 10.71 | 10.71 | 10.13 | 10.02 | 10.07 | 10.07 | 10.07 | 10.07 | 10.03 | 10.03 |
18.73 | 19.37 | 18.09 | 17.18 | 12.86 | 8.34 | 12.52 | 9.77 | 8.05 | 7.08 | 13.02 | 10.91 | 11.04 | |
Total Assets | 38.72 | 38.73 | 36.80 | 35.17 | 30.26 | 24.83 | 23.16 | 20.41 | 18.65 | 17.64 | 23.53 | 21.37 | 21.59 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
-3.13 | 1.11 | -0.32 | -2.09 | 1.78 | 3.67 | 0.64 | 1.68 | 2.20 | 0.47 | -0.36 | -0.28 | |
-0.22 | -0.11 | -0.14 | -0.08 | 0.00 | 0.34 | 0.12 | 0.03 | -0.01 | 0.00 | 0.00 | 0.14 | |
3.03 | -0.45 | 0.41 | 2.33 | -1.98 | -3.78 | -1.00 | -2.25 | -1.55 | -0.48 | 4.59 | -2.92 | |
Net Cash Flow | -0.32 | 0.55 | -0.05 | 0.17 | -0.20 | 0.23 | -0.24 | -0.55 | 0.64 | -0.01 | 4.23 | -3.07 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 41.71 | 136.36 | 186.35 | 249.47 | 382.94 | 233.66 | 254.24 | 140.60 | 97.90 | 66.22 | 94.95 | 52.77 |
Inventory Days | 33.12 | 61.24 | 125.11 | 50.63 | 28.42 | 36.10 | 55.02 | 47.76 | 12.70 | 145.00 | 84.81 | 60.83 |
Days Payable | 44.99 | 113.65 | 149.93 | 72.93 | 32.86 | 97.60 | 173.11 | 98.93 | 88.07 | 285.00 | 122.38 | 45.10 |
Cash Conversion Cycle | 29.84 | 83.96 | 161.52 | 227.17 | 378.50 | 172.15 | 136.15 | 89.43 | 22.53 | -73.78 | 57.38 | 68.50 |
Working Capital Days | 47.69 | 107.67 | 165.52 | 218.17 | 306.56 | 103.69 | 434.85 | 318.88 | 228.60 | 625.27 | 113.84 | 209.13 |
ROCE % | -33.46% | 3.39% | 0.52% | -1.13% | -1.13% | 1.43% | -4.39% | 2.84% | 5.07% | -2.55% | 8.22% | 9.42% |
Documents
Announcements
- Certificate As Per Regulation 40(9) Of The Listing Obligations And Disclosure Requirement Regulation, 2015 For The Year Ended 31St March, 2024. 12 Apr
-
Compliance Certificate For The Period Ended March 31, 2024.
11 Apr - Certificate as per Regulation 7 (3) of the Listing Obligations and Disclosure Requirement Regulation, 2015, for the year ended March 31, 2024.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
8 Apr - Depository and Participants) Regulations, 2018, We have received confirmation certificate from our RTA i.e. Link Intime India Pvt. Ltd. that there were no dematerialization received …
-
Announcement under Regulation 30 (LODR)-Retirement
31 Mar - Mr. Vinayak Desai (DIN: 03185850), has completed his second and final term as an Independent Director and consequently ceased to be a Director of the …
- Closure of Trading Window 28 Mar
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2009
from bse
Business Overview:[1][2]
PLL is a part Naxpar Group and is a WHO-approved and EHS-compliant Company. It is into contract manufacturing of Liquid Orals, Capsules, Ointments, External Powders & Tablets with its manufacturing facility located
at Silvassa.